Aleniglipron
GSBR-1290 · Structure Therapeutics
Once-daily oral small-molecule GLP-1 receptor agonist.
Selected study results
ACCESS · primary Phase 2b publicationMean body-weight change · primary endpointBody weight decreased 12.1% · 36 weeks · Phase 2b
Mean body-weight change · primary endpoint · 36 weeks
Study focus: Weight management
Adults with obesity or overweight and a weight-related comorbidity · 45, 90 or 120 mg once daily · Trial N=230 · Efficacy estimand; least-squares mean change. Results & methods ↗ · Publication ↗
| Daily dose | Weight change | Placebo-adjusted difference |
|---|---|---|
| 45 mg | −9.0% | −8.2 pp |
| 90 mg | −10.7% | −9.8 pp |
| 120 mg | −12.1% | −11.3 pp |
| Placebo | −0.8% | — |
Placebo-adjusted differences are percentage points, not total active-arm weight reduction. Confidence intervals and P values were not adjusted for multiplicity. The separate 44-week ACCESS II sponsor estimate is shown below.
ACCESS IIPlacebo-adjusted weight-loss differencePlacebo-adjusted weight-loss difference: −16.3 percentage points · 44 weeks · Phase 2
Placebo-adjusted weight-loss difference · 44 weeks
Study focus: Weight management
Placebo-adjusted difference, not the total change in the active arm.
Adults in the ACCESS II obesity study · 180 mg once daily · N not included in this summary · Sponsor topline; placebo-adjusted estimate. Results & methods ↗
Placebo-adjusted percentage-point difference, not total loss from baseline. Sample size and full analysis details are not reproduced in this summary.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Mechanism at a glance
Obesity stage by formulation
Latest: Phase 3 ACCOMPLISH chronic weight-management program initiated August 2026.
Next: ACCOMPLISH outcomes; ACCESS follow-up.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies2 records
ACCOMPLISH-1
Weight managementAdults with obesity or overweight and at least one weight-related comorbidity; registrational weight-management study.
ACCOMPLISH-2
Weight management with type 2 diabetesAdults with obesity or overweight and type 2 diabetes; registrational weight-management study.
Phase 2 studies2 records
ACCESS
Weight managementAdults with obesity or overweight and at least one weight-related comorbidity; published dose-ranging study.
ACCESS II
Weight managementHigher-dose study in adults with obesity or overweight and at least one weight-related comorbidity.
Related conditions and outcomes
Phase 2 studies1 record
Body-composition study
Body composition / lean massEvaluates aleniglipron-associated changes in body composition in adults with obesity.
